Inex Marqibo Phase III Preparation Includes Company Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will reduce its workforce from 165 to 62 employees, including executive-level resignations. Inex plans a Phase III comparative trial of the liposomal vincristine product in first- or second-line non-Hodgkin’s lymphoma or acute lymphoblastic leukemia following a negative advisory committee review for third-line NHL.